Johnson & Johnson (J&J) has seen its stock rise by 42.1% over the past year even as it confronts more than 73,000 lawsuits related to talc-based products, including a recent ruling that found it liable for asbestos exposure, costing the company $1.5 billion in damages. Despite these legal hurdles, J&J's Innovative Medicine unit posted a 3.4% sales increase in 2025, and the company anticipates accelerating growth in this segment through 2026 due to new product approvals and a robust operational performance.
“Johnson & Johnson’s JNJ stock · has been trading · above its 50-day and 200-day SMAs · since the end of June”
“Johnson & Johnson · achieved the golden cross · mid-July”
“Johnson & Johnson’s Innovative Medicine unit · is showing · a growth trend”
“J&J’s Innovative Medicine segment's sales · rose · 3.4% in the first nine months of 2025 · on an organic basis”
“Sales of J&J’s Innovative Medicine unit · are negatively impacted by · the loss of exclusivity of Stelara”
“J&J expects · accelerated growth in 2026 · for the Innovative Medicine segment”
“Johnson & Johnson · has rapidly advanced · its pipeline this year”
“J&J believes · icotrokinra has the potential to revolutionize · the treatment of plaque psoriasis · with a once-a-day pill”
“J&J lost U.S. patent exclusivity · of · Stelara · in 2025”
“Stelara accounted for · around 18% of · J&J’s Innovative Medicine unit’s sales in 2024”
“J&J expects · a negative impact of · approximately $2 billion in sales · due to the Medicare Part D redesign in 2025”
“Johnson & Johnson's stock · has risen · 42.1% in the past year”